Group 1 - The core viewpoint of the news is that YuDe Investment has conducted research on a listed company, focusing on its performance and strategic initiatives in the face of market challenges [1] Group 2 - The company, BioShares, is facing challenges such as macroeconomic upgrades and cyclical adjustments in the breeding industry, but it is maintaining revenue growth through innovation and business model optimization [1] - Key products, including foot-and-mouth disease vaccines and circular ring vaccines, have seen significant sales growth, leading to an increase in market share [1] - The company has achieved breakthroughs in vaccine development, including clinical approval for African swine fever subunit vaccines and mRNA vaccines for feline infectious peritonitis, with expectations for market launch between 2027 and 2028 [1]